Instil Bio, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Instil Bio, Inc. (TIL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $12.13 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-03-27
- Instil Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $0.39.
- Instil Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $12.13, a 27.10% decline from fiscal 2024.
- Instil Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $16.64.
- Instil Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Instil Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $29.44, a 6590.91% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $12.13 10-K · filed 2026-03-27 | ||||
| 2024-12-31 | $16.64 10-K · filed 2026-03-27 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-04 | ||||
| 2022-12-31 | $29.44 10-K · filed 2024-03-21 | $1.47 10-K · filed 2023-03-31 | |||
| 2021-12-31 | $0.44 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $0.41 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $0.39 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $0.39 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | $0.62 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |